Tasso

What Tasso does

Tasso, Inc. is a Seattle-based privately held medical device company founded in 2012 by Ben Casavant, PhD, and Erwin Berthier, PhD, that develops patient-centric, virtually painless capillary blood collection devices. Its core product line includes the FDA Class II 510(k)-cleared Tasso+ and Tasso Mini blood lancets, which collect whole liquid blood samples from the upper arm without traditional venipuncture, and the Tile-T20 dried blood spot cartridge, the first DBS cartridge designed specifically for patient-centric blood lancets. The company sells exclusively to enterprise customers through direct field sales and exclusive channel partnerships (InnoVero for global anti-doping and Tasso-SNBL, Ltd. for Japan), generating revenue from device sales, recurring consumables (kits and cartridges), and end-to-end Tasso Care services including kit fulfillment, live proctoring, SMS reminders, and sample tracking via the Tasso Connect portal.

Tasso's primary customer segments are pharmaceutical companies and CROs running decentralized clinical trials, healthcare providers and hospital networks, research foundations and academic medical centers, anti-doping organizations, and digital health and telehealth platforms. Named enterprise customers include the Parkinson's Foundation (30,000+ enrollees in the PD GENEration study), The Leukemia & Lymphoma Society, ARUP Laboratories (assay validation partnership), Randox Health, Biodesix, Catapult Health, Thriva Health, Zoe Health, SheMed, Neurogen Biomarking, Lindus Health, Aptar Digital Health, United BioSource, and InnoVero. The company has shipped over 2 million devices cumulatively as of October 2025 and operates in 60+ countries across all 50 U.S. states.

The business model is B2B enterprise sales with quote-based, multi-year contracts and no direct-to-consumer availability. Tasso augments device revenue with recurring kit and consumables streams plus managed services for decentralized trial logistics. Regulatory clearances span FDA Class II 510(k) (US), CE Mark (EU), Health Canada, and Japan PMDA controlled medical device certification via the Tasso-SNBL joint venture. The company has raised approximately $135M+ in cumulative funding, anchored by a $100M Series B led by RA Capital Management in December 2021, and maintains SOC 2 Type 2 certification across all five Trust Services Criteria, renewed annually since 2023.

Name

Tasso

Legal name

Tasso, Inc.

Website

https://tassoinc.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Tasso is a Seattle-based medical device company that develops FDA-cleared, virtually painless capillary blood collection devices (Tasso+, Tasso Mini, Tile-T20) sold exclusively to enterprise customers including pharmaceutical companies, CROs, research foundations, healthcare providers, and anti-doping organizations for decentralized clinical trials and remote diagnostic testing.

Ownership category

akta.pro rank

Product category

Blood Collection Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industry

Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Capillary blood collection
• Decentralized clinical trials
• Patient-centric diagnostics
• Dried blood spot devices
• Remote blood sampling

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Blood Collection Device Sales: Sale of Tasso+ and Tasso Mini blood collection devices to healthcare organizations, pharmaceutical companies, CROs, and research institutions for clinical and diagnostic applications.
2. Kits and Consumables: Recurring sales of collection kits including the TS Blood Collection Kit, Tile-T20 cartridges, and other consumables for sample collection and shipping.
3. End-to-End Services: Tasso Care platform services including kit fulfillment, logistics management, live proctoring, sample processing coordination, and API integration services for decentralized clinical trials.
4. Testing Services Partnership: Partnership with ARUP Laboratories for combined at-home blood testing services for clinical research, where Tasso provides collection and ARUP provides biomarker testing.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Tasso designs, manufactures, and sells virtually painless, patient-centric capillary blood collection devices—primarily the FDA-cleared Tasso+ and Tasso Mini lancets and the Tile-T20 dried blood spot cartridge—paired with the Tasso Connect end-to-end logistics platform that handles kit shipping, live proctoring, sample tracking, and API integration. The company sells exclusively to organizations (pharma, CROs, healthcare providers, research foundations, anti-doping bodies, and digital health platforms) to enable decentralized clinical trials, remote diagnostic testing, and at-home sample collection across more than 60 countries.

Product overview

Tasso offers a platform-plus-devices architecture centered on patient-centric, virtually painless blood collection solutions. The core product line includes Tasso+ and Tasso Mini blood lancet devices for collecting whole liquid blood or dried blood spot samples, complemented by the Tile-T20 dried blood spot cartridge and supporting services including the Tasso Connect logistics platform and Tasso Care for Prescreening. The portfolio enables decentralized clinical trials, remote patient monitoring, and at-home diagnostic testing across pharmaceutical, clinical research, anti-doping, and healthcare applications.

Differentiator

Problem solved

Functional benefit

Brands

• Tasso+: FDA Class II 510(k)-cleared blood lancet that collects whole liquid blood samples. Multiple standard collection tubes are compatible.
• Tasso Mini
• Tile-T20
• Tasso Care

Products and services

• Tasso+ A virtually painless blood lancet device that collects whole liquid blood samples directly into multiple standard collection tubes. FDA Class II 510(k)-cleared and CE Marked; designed for pharmaceutical clinical trials, decentralized research, and at-home diagnostics use cases.
• Tasso Mini A compact blood lancet device that collects whole blood samples, optimized for sensitive populations and applications requiring longitudinal or higher-frequency sampling. FDA Class II 510(k)-cleared, CE Marked, and licensed with Health Canada.
• Tile-T20 Dried Blood Spot Cartridge A dried whole blood cartridge that collects four precise, volumetrically-controlled blood samples, designed for clinical trials and anti-doping testing; compatible with Tasso Mini and Tasso+ devices.
• Tasso Kits At-home blood collection kits bundling Tasso devices with prepaid shipping materials, pre-labeled barcoded samples, and supporting components to enable remote sample collection and logistics.
• TS Blood Collection Kit A self-administered blood collection kit produced by Tasso-SNBL, Ltd. (Tasso's joint venture with Shin Nippon Biomedical Laboratories), certified as a controlled medical device under Japan's PMDA, enabling distribution of Tasso technology in the Japanese market.
• Tasso Care for Prescreening An end-to-end services solution supporting clinical trial prescreening through remote blood collection and analysis, including kit fulfillment, logistics, live proctoring, and sample processing coordination.
• Tasso Connect Platform An end-to-end logistics platform managing shipping of at-home blood collection kits, live proctoring, SMS reminders, sample tracking, and transport to analytical laboratories, with API integration for partners to link with their own systems.

Quantifiable outcome

• One in three patients delay or avoid diagnostic blood tests due to anxiety, pain, and inconvenience (Tasso survey, October 2024)
• +5 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and secondary.

• Neurogen BiomarkingcoreStrategic or Co-development Partner · 20 November 2025Neurogen adopted Tasso's virtually painless blood collection technology for its Alzheimer's testing platform. The platform combines in-home blood collection, digital cognitive assessment, and telehealth neurology consultations. Tasso technology enables comfortable, user-friendly blood sample collection for early Alzheimer's diagnosis.
• SheMedsecondaryStrategic or Co-development Partner · 27 August 2025UK-based women's healthcare company partnered with Tasso to deliver safer, more personalized weight loss treatments through convenient at-home diagnostics using Tasso+ blood collection device. Every patient completes comprehensive lab screening before GLP-1 treatment. Program has treated thousands of women across the UK.
• Shin Nippon Biomedical Laboratories (SNBL)coreChannel Partner/ Reseller/ Distributor · 27 March 2025Established joint venture Tasso-SNBL, Ltd. for exclusive distribution of Tasso's proprietary on-demand blood collection device in Japan. The JV holds exclusive rights to import and distribute Tasso products in Japan. TS Blood Collection Kit received certification as controlled medical device under Japan's Pharmaceuticals and Medical Devices Act in September 2025.
• ARUP LaboratoriescoreStrategic or Co-development Partner · 3 February 2025Partnership to develop and operationalize high-quality at-home blood testing services for clinical research. ARUP provides biomarker testing using capillary blood collected with Tasso devices. ARUP has validated rheumatoid factor, hsCRP, creatinine, and high-sensitivity DNA testing using Tasso samples. ARUP offers 3,000+ laboratory tests prequalified by pharmaceutical companies.
• Lindus HealthsecondaryStrategic or Co-development Partner · 4 June 2024Lindus Health adopted Tasso's virtually painless remote blood collection technology for clinical trials. The collaboration allows participants to collect blood samples at home without mobile phlebotomists, reducing patient burden and trial costs while improving recruitment and retention.
• The Leukemia & Lymphoma SocietysecondaryStrategic or Co-development Partner · 30 May 2024Collaboration to accelerate blood cancer research by combining Tasso's capillary blood collection technology with LLS's research focus. Includes clinical trial evaluating patient-centric Complete Blood Count (CBC) analysis using Tasso devices in blood cancer patients with low blood counts.
• Parkinson's FoundationcoreStrategic or Co-development Partner · 23 April 2024Partnership to expand and accelerate genetic research into Parkinson's disease through PD GENEration study. Tasso's end-to-end sample collection and logistics platform enables data collection for this landmark international genetics study. More than 30,000 people with PD have enrolled, with nearly half using Tasso's at-home devices.
• Randox HealthsecondaryStrategic or Co-development Partner · 28 November 2023Randox Health, the largest healthcare diagnostics company in UK and Ireland, first to offer Tasso's patient-centric remote sampling device for at-home and in-clinic health tests.
• United BioSource LLC (UBC)secondaryStrategic or Co-development Partner · 27 June 2023Partnership to provide efficient, streamlined sample collection and analysis options for post-approval research. Tasso's at-home blood collection combined with UBC's late-stage research expertise and real-world data infrastructure. Jointly awarded a late-stage biomarker monitoring study.
• Aptar Digital HealthsecondaryStrategic or Co-development Partner · 13 June 2023Collaboration to offer Aptar Digital Health end-users access to Tasso's devices for blood collection. Tasso devices available to patients in Aptar's randomized clinical trials and real-world studies, as well as digital therapeutics and disease management platforms.
• InnoVerocoreChannel Partner/ Reseller/ Distributor · 9 July 2021Exclusive worldwide distributor of Tasso blood collection solutions for anti-doping marketplace. Partnership initiated in 2021 and extended in July 2024. Joint solutions deployed at 2026 Olympic Winter Games, 2024 Paris Olympics, and 2022 FIFA World Cup. InnoVero provides SAFESystem tamper-evident technology combined with Tasso's collection devices.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Drawbridge Health: Drawbridge Health developed the OneDraw device, a virtually painless capillary blood collection device for at-home sample collection — directly competing with Tasso+ and Tasso Mini in patient-centric microsampling for diagnostics and clinical research.
• Yourbio Health (formerly Seventh Sense Biosystems): Yourbio's TAP device is a needle-free capillary blood collection platform with similar decentralized clinical trial and remote testing applications; competes head-to-head with Tasso in patient-centric blood collection for pharma/CRO customers.
• Babson Diagnostics: Babson Diagnostics uses capillary blood samples for retail diagnostics in partnership with retail pharmacies; directly competes in the at-home/microsample blood testing value chain where Tasso also plays via partners like Randox, Thriva, and Zoe.
• Trajan Scientific (Neoteryx Mitra): Trajan's Neoteryx Mitra device is a leading volumetric dried blood spot microsampling tool widely used in decentralized clinical trials and remote sampling; competes with Tasso's Tile-T20 cartridge in the DBS microsampling category.
• Capitainer: Capitainer develops volumetric dried blood spot microsampling cards designed for self-sampling and remote biobanking; overlaps with Tasso's Tile-T20 and DBS offering for clinical trials and remote patient monitoring.
• Velano Vascular: Velano Vascular focuses on needle-free, vascular-access blood collection for hospital and inpatient settings; comparable in mission (less-painful blood collection) but with a different care-setting focus than Tasso's at-home and decentralized trial positioning.
• Lindus Health: Anti-CRO operating decentralized clinical trials and explicitly a Tasso customer; competes for the same pharma-sponsored trial workflows that drive Tasso's DCT-related revenue.

Broad incumbents

• Becton Dickinson (BD): BD is the dominant incumbent in conventional blood collection (Vacutainer, needles, syringes) and is expanding into capillary and remote sampling. With massive scale, established CRO/pharma contracts, and global distribution, BD represents both a partnership channel and the principal incumbent threat to Tasso's growth.
• Bio-Rad Laboratories: Bio-Rad is a diversified diagnostics and life science research manufacturer with overlap in dried blood spot workflows and clinical trial laboratory services; serves many of the same CRO and research customers as Tasso.

Emerging players

• Medable: Medable is a leading decentralized clinical trial platform; integrates with remote blood collection providers like Tasso and is therefore both a potential channel partner and an adjacent competitor for the DCT workflow layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TassoInc
• LinkedInlinkedin.com/company/tasso-inc-

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tasso